Detection of ESR1 mutations in circulating cell-free DNA from patients with metastatic breast cancer treated with palbociclib and letrozole.

Oncotarget · 2017 · PMC5620144 · PMID 28978004

Europe PMC DOI

hedged sentences

0.0470

closest p · 0.9× alpha

0.1800

boldest claim

The sentences

approached significanceP-value=0.047actually significant

Hence, faster progression was seen in the ESR1-mutant group, but this only approached significance (HR=0.31; 95% CI: 0.05-0.95, log-rank P-value=0.047).

also in 8,237 other papers

a trend towards significanceP-value=0.18not close (p > 0.1)

Furthermore, median OS in the ESR1- de novo mutant group was 12.0 months with a trend towards significance for faster progression (HR=0.32; 95% CI: 0.02-2.1, P-value=0.18).

also in 2,760 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.